A Polygenic Risk Score Assessment Reveals More Screening Participants with Clinically Significant Prostate Cancer Than Those Who Would Be Identified with PSA or MRI By Ogkologos - April 30, 2025 586 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the BARCODE1 study Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR Living With Stage 4 Lung Cancer: How Genomic Testing Is Helping... March 15, 2022 Erdafitinib Prolongs Survival in Patients with Metastatic Urothelial Carcinoma and FGFR... November 3, 2023 FDA Grants Accelerated Approval to Sevabertinib for Non-Squamous NSCLC November 27, 2025 Picking out the sound of tumours June 18, 2020 Load more HOT NEWS Study Suggests Watching Disney Movies May Improve Quality of Life for... COVID-19 May Have Saved a Woman’s Life by Helping Her Discover... Biomarker Analyses in Patients with HER2-positive or HER2-low Gastric and Gastro-oesophageal... Penn State Researchers Working on Amazon Alexa Skill for Metastatic Breast...
